
|Articles|December 1, 2003
CMS Ready to Impose Plan Reform
Dermatologists who administer chemotherapy and other drugs in their offices could see significant reductions in reimbursement levels as a result of an effort by the federal government to curtail Medicare's costs for drugs used to treat cancer.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Off-Label Case Series: Topical Roflumilast for Mild HS
4
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
5


















